| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | 0.0092 | 0.7 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
| mRNA | XL765 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | 0.01 | 0.7 |
| mRNA | SB52334 | GDSC1000 | pan-cancer | AAC | -0.011 | 0.7 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.7 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.01 | 0.7 |